Literature DB >> 30917397

Changing trends of incidence and prognosis of thyroid carcinoma.

Jamshid Farahati1, Uwe Mäder2, Elena Gilman1, Rainer Görges3, Ines Maric1, Ina Binse3, Heribert Hänscheid2, Ken Herrmann3, Andreas Buck2, Andreas Bockisch3.   

Abstract

AIM: to evaluate the time trend of epidemiology of follicular cell derived thyroid cancer (TC) based on data from a well documented cancer registry.
METHODS: Population based data on TC from Lower Franconia (LF), Germany, within 1981 and 2015 were analysed to estimate the regional epidemiology of TC. The incidence was assessed in 5-year-intervals for gender, histology, and tumor stage.
RESULTS: Incidence of TC solely attributable to papillary TC (PTC) doubled mainly in T1- and T2-stages within the evaluation period from 4.5 to 8.7/100.000/y in females and 1.7 to 4.1/100.000/y in males. There was no significant change of follicular TC (FTC), whereas anaplastic TC (ATC) decreased in the same interval. The number of lymph-node metastases and T3-cases increased, while the frequency of T4-stage and distant metastases decreased. Increased incidences of T1- and T2-stages suggest an over-diagnosis. In contrast, increasing number of tumors at T3-stage and with lymph node involvement contradict the over-diagnosis as the only reason for rising incidence. Declining of T4-stages in spite of increasing of T3-stages and N1-cases indicates the value of timely detection and treatment of TC. In accordance, reduced incidence of advanced cancers with M1-stage and ATC cases promote our current management of TC.
CONCLUSION: Timely diagnosis and adequate risk-adopted treatment of thyroid cancer reduce the frequency of high-risk cases with distant metastases and the possible protracted dedifferentiation of TC to anaplastic features. Our analyses support the management algorithm in thyroid cancer according to the recent guidelines of German Nuclear Medicine Society. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 30917397     DOI: 10.1055/a-0859-7454

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  4 in total

1.  Analysis of Risk Factors Associated With Central Lymph Node Metastasis in Papillary Thyroid Carcinoma With cT1N0 Stage.

Authors:  Yin-Zhu Zhao; Nian-An He; Xian-Jun Ye; Fu Jin; Meng-Xue Li; Xianxian Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-03       Impact factor: 6.055

2.  MicroRNA-384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB.

Authors:  Yongxia Wang; Beixi Wang; Hong Zhou; Xiangnan Zhang; Xinlai Qian; Jing Cui
Journal:  Biomed Res Int       Date:  2020-01-09       Impact factor: 3.411

Review 3.  Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.

Authors:  Maximilian J Reinecke; Gerrit Ahlers; Andreas Burchert; Friederike Eilsberger; Glenn D Flux; Robert J Marlowe; Hans-Helge Mueller; Christoph Reiners; Fenja Rohde; Hanneke M van Santen; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-23       Impact factor: 10.057

Review 4.  Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Histol Histopathol       Date:  2020-11-10       Impact factor: 2.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.